Observed and Predicted Risk of Breast Cancer Death in Randomized Trials on Breast Cancer Screening.

ABSTRACT:

Background

The role of breast screening in breast cancer mortality declines is debated. Screening impacts cancer mortality through decreasing the number of advanced cancers with poor diagnosis, while cancer treatment works through decreasing the case-fatality rate. Hence, reductions in cancer death rates thanks to screening should directly reflect reductions in advanced cancer rates. We verified whether in breast screening trials, the observed reductions in the risk of breast cancer death could be predicted from reductions of advanced breast cancer rates.

Patients and methods

The Greater New York Health Insurance Plan trial (HIP) is the only breast screening trial that reported stage-specific cancer fatality for the screening and for the control group separately. The Swedish

SUBMITTER: Autier P 

PROVIDER: S-EPMC4839680 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature